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AbstrAct
Objectives To investigate the acute and adaptation 
cardiovascular and metabolic training responses in people 
with Parkinson’s disease (pwP).
Design (1) A cross-sectional study of exercise response 
of pwP compared with sedentary controls and (2) an 
interventional study of exercise training in pwP.
setting Community leisure facilities.
Participants pwP (n=83) and sedentary controls (n=55).
Interventions Study 1 included participants from a two-
arm-parallel single-blind phase II randomised controlled 
trial (RCT), that undertook a baseline maximal incremental 
exercise test and study 2 included those randomised to 
the exercise group in the RCT, who completed a 6-month 
weekly exercise programme (n=37). The intervention 
study 2 was a prescribed exercise program consisting of 
sessions lasting 60 min, two times a week over a 6-month 
period. The control group followed the same protocol 
which derived the same cardiorespiratory parameters, 
except that they were instructed to aim for a cadence of 
~60 revolutions per minute and the unloaded phase lasted 
3 min with an initial step of 25 W.
Primary and secondary outcome measures Stepwise 
incremental exercise test to volitional exhaustion was the 
primary outcome measure.
results Study 1 showed higher maximum values for 
heart rate (HR), VO2 L/min, VCO2 L/min and ventilation L/
min for the control group; respiratory exchange ratio (RER), 
perceived exertion and O2 pulse (VO2 L/min/HR) did not 
differ between groups. In study 2, for pwP who adhered to 
training (n=37), RER increased significantly and although 
there was no significant change in aerobic capacity or HR 
response, reduced blood pressure was found.
conclusions An abnormal cardiovascular response to 
exercise was observed in pwP compared to controls. After 
the exercise programme, metabolic deficiencies remained 
for pwP. These observations add to the pathogenic 
understanding of PD, acknowledge an underling metabolic 
contribution and support that certain cardiovascular 
symptoms may improve as a result of this type of 
exercise.
IntrODuctIOn 
Parkinson’s disease (PD) is a progres-
sive disorder primarily associated with 
motor symptoms resulting from abnormal 
activity in basal ganglia motor circuits, 
and also presenting with dysfunctions of 
the autonomic, metabolic and cardiovas-
cular systems.1 Pharmaceutical interven-
tions are the primary treatment option, but 
exercise has been formally recognised as 
a disease-management option for people 
with PD (pwP); as such this is an important 
research area.2 There is strong evidence 
supporting beneficial effects of exercise 
programme both in normal ageing and 
in PD.3 In addition, according to research 
evidence, there is a connection between the 
frequency of weekly exercise and physical 
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Research
strengths and limitations of this study
 ► Our study explores for the first time the extent 
and nature of previously suggested altered 
cardiovascular and metabolic responses in people 
with Parkinson’s disease using a 6-month exercise 
intervention in a relatively large sample.
 ► Our findings support previous work that indicate 
Parkinson’s is also a disorder of metabolic and 
energy-producing systems which would explain 
fatigue symptoms and provide a more targeted 
approach for exercise therapies for fatigue and open 
avenues for drug therapies.
 ► This project was a secondary analysis of a 
pragmatic trial, with a small number of participants 
on medications that may have impacted on the 
exercise response.
 ► There was no direct measurement of mitochondria 
and autonomic dysfunction for the purpose of this 
study.
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function in PD.4 Walking speed, balance and executive 
function—specifically cognitive flexibility and working 
memory—of pwP can improve following adherence to a 
high-frequency exercise programme.4 5 However, while 
there is compelling data that exercise benefits motor 
symptoms,6 functioning, quality of life and cognition,4 7 
the optimal exercise type and dose is yet to be identi-
fied. It is also not clear as to what extent reduced risk 
of PD is associated with higher physical activity levels,8 
and improvements observed in motor symptoms after 
exercise interventions can be attributed to metabolic or 
motor mechanisms.6 9 Gaining a better understanding 
of the mechanisms underpinning the exercise effect is 
important, as it will lead to more targeted and optimal 
physical activity interventions. Exercise training that 
involves repetitive movement has been shown to acti-
vate neuromuscular systems and improve motor func-
tioning.7 10 Furthermore, progressive resistance training 
programme has been found to have a positive effect on 
cardiovascular autonomic regulation in PD and improve 
systolic blood pressure response to orthostatic stress.11 
However, less is known about cardiovascular and meta-
bolic responses to exercise training.1 Previous studies 
investigating peak responses during cardiopulmonary 
exercise tests in pwP have contradictory results.1 Further-
more, while studies have consistently found that exer-
cise capacity is reduced, we do not know the extent to 
which this is attributable to deconditioning and blunted 
cardiovascular responses relating to impaired autonomic 
functioning,1 or to reduced aerobic metabolic responses 
because of mitochondrial dysfunction in PD.1 12 13 Careful 
comparisons of the cardiovascular and metabolic exer-
cise response and adaption to training with healthy indi-
viduals of similar activity levels have yet to be performed.
The aim of this research was to explore the acute cardio-
vascular and metabolic response to exercise and the extent 
of their adaptation in response to a 6-month combined 
strength and cardiovascular training programme for pwP.
MethODs
Design
This research is formed from two studies: (1) a cross- 
sectional study of exercise response of pwP compared 
with a sedentary healthy control group and (2) an inter-
ventional study of exercise training in pwP.
Data for pwP were obtained from a two-arm-parallel 
single-blind phase II randomised controlled trial (RCT) 
(registered with ClinicalTrials.Gov (NCT01439022) of 
community-delivered exercise for pwP).9 The cross- 
sectional study 1 included all participants from the RCT 
(all participants before randomisation to exercise and 
handwriting group) that undertook a baseline maximal 
incremental exercise test and the interventional study 2 
included those randomised to the exercise group in the 
RCT.
Data for the healthy control group for the cross- 
sectional study of exercise response were obtained from 
people recruited by the Oxford Cognitive Therapy Centre 
(https://www. octc. co. uk).
setting
For the above registered RCT,9 Parkinson’s assessments 
were carried out at the Movement Science Laboratory, 
Oxford Brookes University, Oxford, UK. The exercise 
group’s intervention took place at community leisure facil-
ities in Oxfordshire and Berkshire and the control inter-
vention was handwriting practice at participants home. 
The healthy controls, whose data were used for the base-
line comparison (study 1), underwent assessment at the 
Cardiovascular Clinical Research Facility, John Radcliffe 
Hospital, Oxford. Both testing centres collaborate on a 
regular basis and work under similar standard operating 
procedures (SOPs) and guidance; biocalibrations have 
been performed between sites to ensure consistency.
Participants
People with idiopathic PD were recruited from neurology 
clinics and general practitioner practices in the Thames 
Valley, UK, and though local Parkinson’s UK group 
meetings. 
Inclusion criteria for pwP were: (1) diagnosis of idio-
pathic PD (as defined by the UK Parkinson’s Disease 
Society Brain Bank clinical diagnostic criteria 14; (2) able 
to walk ≥100 m. Exclusion criteria were: (1) dementia; 
(2) history of additional prior neurological condition; 
(3) severe depression or psychosis or a mental state 
that would preclude consistent active involvement with 
the study over its duration; (4) cardiac precautions that 
would prevent the subject from participating in the inter-
vention; (5) any known contraindication to exercise; (6) 
reduced cognitive function of any cause (Mini-Mental 
State Examination <23) and (7) an orthopaedic condi-
tion that limited independent walking. Participants’ 
medication was continued as normal and was recorded.
The control group were recruited from the local 
via media and poster advertisement. The study 
received National Health Service ethical approval 
(NRES Committee South Central—Oxford B Ref: 10/
H0605/48). Inclusion criteria for controls were: (1) 
self-reported participation in fewer than 60 min/week of 
physical activity sufficient to raise their heart rate (HR), 
(2) had no known contraindications to MRI scanning or 
fitness testing (assessed using the Physical Activity Read-
iness Questionnaire (physical activity R-Q). Exclusion 
criteria were: (1) a history of major vasculature problems 
or receiving HR-controlling medication, (2) self-reported 
history or current investigation of a neurological disorder 
or symptoms or treatment for a psychiatric illness within 
the past year and (3) ability to commit to the require-
ments of study.
Intervention
The intervention for pwP was a prescribed exer-
cise programme consisting of sessions lasting 60 min, 
two times a week over a period of 6 months. Participants 
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self-managed their exercise scheduling in relation to 
their medication; a detailed description can be found.9 
Process data from the RCT would suggest the individuals 
who underwent the exercise intervention were able to 
manage their exercise scheduling effectively.
The exercise sessions took place at leisure facilities 
in Oxfordshire and Berkshire, UK. Participants were 
able to choose participating facilities nearby their home 
to minimise travel burden. Exercise was supported by 
either a specialist exercise professional (registry of exer-
cise professional’s level 4 qualification in exercise for 
long-term neurological conditions) or a physiotherapist. 
Members of the leisure facility staff working in the gym 
were fully informed about the study and that the partic-
ipants were following a prescribed exercise programme. 
Adherence to prescribed exercise programme was moni-
tored by session workbooks.
The exercise programme totalled 48 sessions over a 
24-week period (2× a week) and each session, which 
lasted 60 min, consisted of the following: At the start 
of each session, the participants performed 30 min of 
aerobic training (plus an initial 10 min warm-up) (55%–
85% age-predicted HRmax (220—age)) and were able to 
choose from on a treadmill, bicycle ergometer, cross-
trainer or rowing ergometer, depending on equipment 
was availability. After an initial warm-up of 10 min, partici-
pants were instructed to aim for 30 min of aerobic training 
and exercise so that HR was maintained in an aerobic 
training zone (medication affecting HR was considered). 
Participants recorded the type of equipment used and 
actual duration, as well as the rating of perceived exertion 
and HR in their training diaries. The aerobic exercise was 
followed by 30 min of resistance training. The resistance 
training schedule consisted of leg presses, leg extensions, 
sit to stands, two-arm pull down, ‘wood chop’ (ie, exercise 
which includes rotation of the trunk, shoulder flexion 
and shoulder adduction—the arm is moving in a diag-
onal direction) and arm raises.
The intervention was personalised and progressed 
according to the following protocols. At the initial session, 
the exercise professional or physiotherapist set the exer-
cise intensity so that each participant achieved 55%–85% 
age-predicted maximal HR.15 16 For the duration of the 
aerobic training, participants were taught to manipulate 
speed or resistance in order to maintain the exercise 
intensity. During the strength training, Initial resistance 
was selected so 10 repetitions could be performed. The 
exercise professional or physiotherapist instructed the 
participants to increase resistance when two full sets 
of 10 could be performed at a given resistance, within 
2 min. This would lead to a resultant decrease in repe-
titions and then the protocol repeated. At the monthly 
support session, exercise intensities and progression was 
monitored.
Only pwP who adhered (did not discontinue intervention) 
to the exercise programme were included in the training 
response analysis. For these participants’ data are reported 
for exercise tests carried out at baseline (assessment 1), 
3 months (assessment 2—midway thought intervention) 
and 12 months (assessment 3—end of intervention).
Demographic information for pwP and the control group 
was recorded at baseline; age, weight and blood pressure 
are reported here. Medical history relating to Parkinson’s, 
including current medication use and score on the Move-
ment Disorder Society Unified Parkinson’s Disease Rating 
Scale (MDS-UPDRS) part III are also reported.
exercise test
For pwP, the exercise test was carried out during ON state 
with participants asked to follow their usual Parkinson’s 
medication regime. PwP experience ON and OFF states 
and the time OFF state occurs since taking medication 
varies considerable between individuals. As such, no time 
of taking medication was directed and people were able 
to take their medication as required. However, assess-
ments were scheduled to fit with individuals’ medication 
regimen and details of ON and OFF states and time since 
medication was recorded via the MDS-UPDRS. Both pwP 
and controls were asked to refrain from the consump-
tion of alcohol, cigarettes, food and caffeine and to avoid 
exercise for a period of 3 hours prior to the assessment.
For pwP test, the exercise test was conducted on an 
electronically braked cycle ergometer (Excalibur Sport, 
Lode, The Netherlands), integrated with a cardio-
pulmonary-monitoring system (Metalyzer 3B, Cortex, 
Germany), that controlled the work rate protocol on 
the ergometer and recorded breath-by-breath measure-
ments of VO2, VCO2, ventilation and HR (via Polar Heart 
Rate Monitor; Polar, Finland) throughout the test. The 
work rate protocol consisted of 2 min steps starting with 
unloaded cycling, then increasing to 50 W, and there 
after by 25 W. While the ergometer maintained a constant 
work load, independent of cadence, participants were 
instructed to aim for cadence of ~50 revolutions per 
minute (rpm). At the end of each step, participants were 
asked to rate their level of exertion (rating of perceive 
exertion) using the borg rating of perceived exertion 
10 point category ratio scale (BORG CR10 scale, 0–10). 
Participants were verbally encouraged to carry on for as 
long as they could and the test was terminated when the 
participant reached volitional exhaustion. The following 
exercise response measures were obtained from the 
cardiopulmonary-monitoring system power output watts 
(Watt), VO2 (litre per minute), VCO2 (litre per minute), 
ventilation (VE litre per minute), respiratory exchange 
ratio (RER =VO2 consumed/VCO2 produced), HR, 
O2 pulse (VO2/HR). Oxygen uptake efficiency slope 
(OUES) was calculated as: VO2=a log VE +b, where 
a=OUES, VO2(litre per minute) and total ventilation 
(VE litre per minute).
The control group followed the same protocol which 
derived the same cardiorespiratory parameters, except 
the they were instructed to aim for a cadence of ~60 rpm 
and the unloaded phase lasted 3 min with an initial step 
of 25 W.
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Figure 1 Study flowchart. The participant flow. For study 1(acute exercise response), 83 pwP and 55 controls were included 
for cross-sectional comparison. For study 2 (Aadaptation to exercise), 37 pwP, who were randomised to exercise in an 
RCTrandomised controlled trial (reported elsewhere) and adhered to the exercise programme, wasere included. PD, Parkinson’s 
disease; pwP, people with PD.
Table 1 Baseline descriptives
PD (study 1: N=83) Control (N=55) PD (study 2: N=37)
Gender Male: 61/Female: 22 Male: 26/Female: 29 Male: 21/Female: 16
Age (years) 67±8 (39–86) 67±5 (60–80) 65±7 (43–77)
Weight (kg) 77±15 (42–108) 78±11 (61–103) 80±17 (52–108)
Dia BP (mm Hg) 82±13 (53–138) 73±8 (57–89) 82±10 (57–102)
Sys BP (mm Hg) 137±22 (75–201) 130±14 (103–175) 134±21 (98–178)
MDS-UPDRS III 17±9 (0–43) NA 16±10 (0–43)
GA light to moderate activity 183±111 (21–526) (n=70) NA 186±125 (31–527) (n=31)
The values are expressed in mean±SD (range).
Dia BP, diastolic blood pressure; GA, GENEActiv; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; NA, 
not applicable; PD, Parkinson’s disease; Sys BP, systolic diastolic blood pressure.
Activity
Physical activity in pwP was measured using the wrist-worn 
activity monitor: GENEActiv. The GENEActiv was worn by 
the participants around the wrist for 7 days following an 
assessment. GENEActiv is a triaxial acceleration sensor 
which is lightweight and waterproof. It sampled at 100 Hz 
for 7 days. The participants sent the monitor back in a 
prestamped, addressed envelope.
The data were downloaded from the device onto the 
computer and transformed into a 60 s epoch excel file. 
An Excel Macro was designed by GENEActiv17 which 
generated minutes per day spent sedentary, performing 
light, moderate or vigorous activities.18 The file that was 
collected from the participants was run through this 
Macro to calculate a total weekly activity count. Finally, 
one outcome was calculated by averaging the data across 
the days.
Analysis
Descriptive statistics were calculated for demographic 
characteristics and session and activity adherence. Inde-
pendent samples t-test, or Mann-Whitney U test was used 
to assess differences between the two groups (pwP and 
controls) at baseline.
Regression analysis was used to determine slopes and 
intercepts for exercise response measures. The average 
the last 30 s of the test was used to calculate maximum 
values of measures. For exercise size response data, a 
linear mixed models procedure of SPSS was used to 
determine the changes in measures, as response vari-
ables, according to three repeated measurements. Alpha 
was set at 0.05.
results
Participants
Participant flow for the pwP recruited to the RCT can 
be found elsewhere.9 A flow diagram for the current 
report can be found in figure 1. Eighty-three pwP took 
part in the exercise test and were included in study 1. 
Thirty-seven people randomised to the exercise group 
that were deemed to adhere to the intervention were 
included in study 2. Fifty-five people were recruited to 
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Table 2 Comparison of acute response to exercise between pwP and control groups 
PD Control P u t
HRmax (beats/min) 136 (114) 152 (108) <0.001 1067
VO2max (L/min) 1.46 (2.35) 1.69 (2.57) 0.008 1909
VCO2max (L/min) 1.74 (2.98) 1.98 (2.67) 0.013 1745
VEmax(L/min) 48.46 (99.12) 63.45 (106.3) <0.001 1405
O2 pulsemax 0.01 (0.02) 0.01 (0.02) 0.850 1756
RERmax 1.19 (0.52) 1.16 (0.45) 0.998 0.003
RPEend test 7 (8) 7 (9) 0.012 1635
HR/Wattsslope 0.37 (0.89) 0.52 (0.75) <0.001 7.363
VO2/Wattsslope 0.01 (0.0080) (0.02) 0.01 (0.0095) (0.01) <0.001 1150
OUESslope 1.7 (2.43) 1.84 (2.45) 0.198 20 224
VO2/Wattsintercept 0.42 (1.01) 0.33 (0.53) <0.001 1222
The values are expressed in median (range).
HR, heart rate; O2pulse = VO2/HR; OUES, oxygen uptake efficiency slope; PD, Parkinson’s disease; pwP, people with PD; 
RER, respiratory exchange ratio; RPE, rating of perceive exertion (CR-10); VE, ventilation.
the control group for study 1. All participants provided 
written informed consent.
Table 1 shows demographic data for participants, 
including the subset of pwP in study 2. The groups were 
similar in age, weight and resting blood pressure; however, 
a great proportion of pwP group were men.
stuDy 1
A comparison of the acute response to exercise between 
pwP and the control group is shown in table 2. The 
control group obtained higher maximum values for HR, 
VO2L/min, VCO2L/min and VE L/min. However, respi-
ratory exchange ratio, perceived exertion and O2 pulse 
(VO2L/min/HR) did not differ between groups. Though 
exercise response parameters (slopes) differed between 
groups, except for OUES, HR and VO2L/min increased 
at a greater rate against work rate in the control group.
stuDy 2
The median number of sessions attended by the pwP 
that did not discontinue the RCT intervention was 40 out 
of the 48 prescribed sessions and most (n=32) attended 
one or more sessions a week on average. In 99% of these 
sessions, the aerobic component was performed with a 
mean (SD) time spent on the aerobic component of 30.2 
(±3.6) min/session. Considering the resistance compo-
nent, in 95% of attended sessions, the two-arm pull-down 
exercise was performed, 93% arm raises, 91% leg press, 
85% sit-to-stands, 80% ‘wood chop’ and 25% leg exten-
sions. Adaption to exercise is displayed in table 3. Individ-
uals went further on the exercise test (Timeend); however, 
no significant change was observed in any other param-
eter, except for a higher respiratory exchange ratio. 
Exercise test time and respiratory exchange ratio were 
the highest at the 3-month assessment (halfway through 
the intervention).
Medications taken by pwP are reported in table 4.
DIscussIOn
This paper highlights key exercise responses for the 
first time; this could lead to a change in the approach 
to exercise prescription for pwP. As expected, we 
observed a blunted exercise capacity in pwP, with 
reduced workload achieved in exercise testing. In 
addition, cardiovascular and metabolic responses 
during exercise, as reflected by lower oxygen utilisa-
tion and HR responses, did not change significantly 
over the course of the interventional study. Impor-
tantly, both groups achieved a maximal level of exer-
cise at the end of the test, as indicated by RER values 
above one, suggesting an anaerobic contribution. PwP 
did not rate effort any higher than the control group, 
which indicates that an overperception of effort or 
leg fatigue, as found in multiple sclerosis,19 was not 
a factor affecting their test termination. In summary, 
we observed both reduced aerobic and cardiovascular 
responses to exercise in pwP who were physically 
active and were pushing themselves hard. When we 
explored the impact of training on both cardiovas-
cular and metabolic systems in the Parkinson’s group, 
we expected to see a typical training effect on exercise 
capacity and cardiovascular and metabolic responses.20 
Instead, we found that while their exercise capacity 
increased there were no significant changes in meta-
bolic measures; rather, any increase in exercise perfor-
mance was likely to be achieved by tolerating a higher 
anaerobic contribution increasing the duration of the 
test.
With regard to the exercise adaptation response, 
our results were different to our hypotheses; there was 
no significant change in the aerobic capacity or HR 
response. However, our findings agree with the results 
group.bmj.com on January 5, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Mavrommati F, et al. BMJ Open 2017;7:e017194. doi:10.1136/bmjopen-2017-017194
Open Access 
Table 3 Long-term response to exercise for the pwP who adhered to training
Baseline 3 months 6 months P
Timeend (s) 682±40 722±39 703±40 0.031
HRmax (beats/min) 138±3 140±4 138±3 0.725
VO2max (L/min) 1.71±0.11 1.66±0.11 1.66±0.09 0.648
VCO2max (L/min) 2.00±0.13 2.02±0.13 1.96±0.11 0.683
VEmax(L/min) 55.01±4.33 55.67±3.71 52.58±4.31 0.724
O2 Pulsemax 0.012±0.001 0.012±0.001 0.012±0.001 0.949
RERmax 1.16±0.02 1.26±0.02 1.18±0.02 0.035
RPEend test 6±0 7±0 7±0 0.300
HR/Wattsslope 0.38±0.02 0.37±0.02 0.36±0.02 0.118
VO2/Wattsslope 0.008±0.000 0.008±0.000 0.008±0.000 0.578
OUESslope 1.85±0.10 1.80±0.09 1.90±0.08 0.279
O2 Pulseslope 1.124±0.86 1.022±0.071 1.008±0.060 0.190
VO2/Wattsintercept 0.41±0.03 0.40±0.02 0.43±0.02 0.486
Dia BP (mm Hg) 82±10 75±11 73±13 >0.001
Sys BP (mm Hg) 133±20 128±19 126±16 0.014
MAP (mm Hg) 99±12 93±12 91±13 >0.001
The values are expressed in mean ±SD.
Dia BP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; O2 Pulse = VO2/HR; OUES , oxygen uptake efficiency slope;  
pwP, people with Parkinson’s disease; RER, respiratory exchange ratio; RPE, rating of perceive exertion (CR-10); Sys BP, systolic diastolic 
blood pressure; VE, ventilation.
Table 4 pwP group medication
DA AChE MAOI AntiDep MiTr betab antiBP CVS Other
Baseline (n=83) 74 15 16 6 1 6 8 0 34
Baseline (n=37) 34 5 1 4 1 3 2 0 14
AChE, anticholinergic drugs; antiBP, other antihypertensive; AntiDep, antidepressant drugs (all); betab, beta blockers; CVS, other drugs 
affecting heart; DA, dopamine agonists; MAOI, mono amine oxidase drug; MiTr, minor tranquiliser; other,  all other drugs; pwP, people with 
Parkinson’s disease. 
of a pilot study, by Skidmore et al21 in which the five 
enrolled participants showed improvement in peak 
walking workload capacity and there was no change 
in VO2 peak, which was measured with open-circuit 
spirometry. This antithesis could be explained by 
either of our two hypothesises: (1) ‘impaired auto-
nomic function’ and (2) ‘mitochondrial dysfunction in 
PD’. Mitochondrial dysfunction in PD might alternate 
O2 supply during exercise.
1 Moreover, lower cardiovas-
cular and metabolic responses could be due to auto-
nomic dysfunction.22 23 PwP present lower elevations in 
HR and BP during exercise; these non-motor features 
are being defined across literature by a dysfunctional 
autonomic nervous system.24
Interestingly, there was a trend to reduce HR in 
response to training, suggesting an improved efficiency 
of the cardiovascular system. We found higher diastolic 
and systolic blood pressure at rest in pwP despite this 
group being relatively active compared with the low active 
control group and achieving over 150 min of activity a 
week. This is in contrast to other studies that have found 
no difference in BP between patients with PD and other-
wise healthy people.25 26
Nevertheless, we found in this per-protocol anal-
ysis, weekly 60 min of combined cardiovascular and 
strength exercise, had a positive effect on reducing 
blood pressure after 3 and after 6 months. This is in 
agreement with the results of a previous study which 
reported a health benefit of reduced blood pressure27 
and a recent study that11 found progressive resis-
tance training had a positive effect on cardiovascular 
autonomic regulation in PD. This supports our find-
ings that cardiovascular changes are normal whereas 
respiratory changes are not, indicating cardiovascular 
adaption to exercise occurs in the absence of effects 
on metabolic systems.
stuDy lIMItAtIOns
This project was a secondary analysis of a pragmatic trial 
with a small number of participants included on medica-
tions that may have impacted on the exercise response. 
group.bmj.com on January 5, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Mavrommati F, et al. BMJ Open 2017;7:e017194. doi:10.1136/bmjopen-2017-017194
Open Access
In addition, there was no direct measurement of mito-
chondria and autonomic dysfunction. Considering the 
complex aetiology with genotype and phenotype presen-
tation, there is now a need to explore individual responses 
in more detail in order to consider more optimal prescrip-
tion to benefit movement. In addition, we did not have 
intervention data for the control in order to compare 
exercise response. However, studies that examined the 
effect of exercise endurance training on VO2 kinetics 
have shown that a training response would be expected 
in this age group.28 29
PwP present improved movement in response to exer-
cise.30 Our findings suggest that pwP have a reduced 
aerobic response during exercise and rely on anaer-
obic metabolism for their capacity gains; at a group 
level, this does not change with training, whereas their 
movement does.9 In order to inform optimal interven-
tion, this needs to be investigated further. In study 2, 
we used a combined training approach and gained 
benefits to movement behaviour which are reported 
elsewhere.9
IMPlIcAtIOns fOr reseArch
PwP had a blunted exercise capacity and in those who 
followed an exercise intervention according to protocol, 
there was a change in cardiovascular parameters associ-
ated to BP, but no change in metabolic parameters. More-
over, our main trial findings show improvement in motor 
symptoms.
There is an identified need for studies that will focus 
on metabolic and cardiovascular changes in PD; espe-
cially substantive RCTs, which will explore cardiovascular, 
metabolic, cognitive and motor symptoms responses to 
different types of structured exercise training in more 
detail. In addition, individualised responses to exercise 
should be further investigated.
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